About NewcelX Ltd.
https://www.newcelx.comNewcelX Ltd., a biotechnology company, engages in developing transformative cell-based and small-molecule therapies for neurodegenerative and metabolic diseases. The company was founded in 2008 and is headquartered in Zurich, Switzerland.
CEO
Ronen Twito
Compensation Summary
(Year )
Total Compensation (Unknown At The Moment)
Industry Biotechnology
Sector Healthcare
Went public October 24, 2025
Full time employees 11
Split Record
| Date | Type | Ratio |
|---|---|---|
| 2025-10-31 | Reverse | 1:10 |
| 2024-09-27 | Reverse | 1:40 |
Ratings Snapshot
Rating : C
Discounted Cash Flow 5
Return On Equity 1
Return On Assets 1
Debt To Equity 1
Price To Earnings 1
Price To Book 2
Overall Score 2
Price Target
Target High $0
Target Low $0
Target Median $0
Target Consensus $0
Market Cap $994500
52w High $33.70
52w Low $1.89
P/E -0.38
Volume 48.28K
Outstanding Shares 450.00K
About NewcelX Ltd.
https://www.newcelx.comNewcelX Ltd., a biotechnology company, engages in developing transformative cell-based and small-molecule therapies for neurodegenerative and metabolic diseases. The company was founded in 2008 and is headquartered in Zurich, Switzerland.
Income Statement
| Period | Revenue | Operating Expense | Net Income | Net Profit Margin | Earnings Per Share | EBITDA |
|---|---|---|---|---|---|---|
| Q2-2025 | $0 | $1.78M ▲ | $-2.22M ▼ | 0% | $-10.5 ▲ | $-2.22M ▼ |
| Q4-2024 | $0 | $1.58M ▼ | $55.02K ▲ | 0% | $-26.3 ▼ | $-1.59M ▲ |
| Q2-2024 | $0 | $2.05M ▼ | $-2.04M ▼ | 0% | $0 ▲ | $-1.94M ▲ |
| Q4-2023 | $0 | $4.26M ▼ | $-4.56K ▲ | 0% | $-1.4 ▲ | $-4.26M ▲ |
| Q2-2023 | $0 | $7.54M | $-7.61M | 0% | $-2 | $-7.54M |
Balance Statement
| Period | Cash & Short-term | Total Assets | Total Liabilities | Total Equity |
|---|---|---|---|---|
| Q2-2025 | $3.07M ▲ | $4.34M ▲ | $1.46M ▲ | $2.88M ▲ |
| Q4-2024 | $1.67M ▲ | $2.23M ▲ | $826.76K ▼ | $1.41M ▲ |
| Q2-2024 | $552.76K | $1.19M | $10.46M | $-9.27M |
Cash Flow Statement
| Period | Net Income | Cash From Operations | Cash From Investing | Cash From Financing | Net Change | Free Cash Flow |
|---|---|---|---|---|---|---|
| Q2-2025 | $-2.22M ▼ | $-2.07M ▲ | $0 ▲ | $3.48M ▼ | $1.41M ▲ | $-2.07M ▲ |
| Q4-2024 | $55.02K ▲ | $-2.74M ▼ | $-3.92K ▼ | $3.85M ▲ | $1.11M ▲ | $-2.74M ▼ |
| Q2-2024 | $-2.04M ▼ | $-1.53M ▲ | $0 | $1.19M ▼ | $-344.92K ▲ | $-1.53M ▼ |
| Q4-2023 | $-4.56K ▲ | $-2.39M ▲ | $0 | $1.63M ▲ | $-753.77K ▲ | $-2.39K ▲ |
| Q2-2023 | $-7.61M | $-7.3M | $0 | $0 | $-7.3M | $-7.3M |
CEO
Ronen Twito
Compensation Summary
(Year )
Total Compensation (Unknown At The Moment)
Industry Biotechnology
Sector Healthcare
Went public October 24, 2025
Full time employees 11
Split Record
| Date | Type | Ratio |
|---|---|---|
| 2025-10-31 | Reverse | 1:10 |
| 2024-09-27 | Reverse | 1:40 |
Ratings Snapshot
Rating : C
Discounted Cash Flow 5
Return On Equity 1
Return On Assets 1
Debt To Equity 1
Price To Earnings 1
Price To Book 2
Overall Score 2
Price Target
Target High $0
Target Low $0
Target Median $0
Target Consensus $0